share_log

Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5

Benzinga ·  Dec 22, 2023 22:32

Piper Sandler analyst Christopher Raymond downgrades AlloVir (NASDAQ:ALVR) from Overweight to Neutral and lowers the price target from $27 to $1.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment